STOCK OPTIONS

6 Months Ended

Jun. 30, 2025

Share-Based Payment Arrangement [Abstract]

NOTE 3 – STOCK OPTIONS

On March 5, 2023, the Board of the Company determined that in the event that the Company’s stock is listed on the Nasdaq Stock Market, then one half of the awarded but unvested option grants made in each of August 2021 and in August 2022, including to officers, directors, will immediately vest at such time. In addition, the Board also determined to provide that following the termination of services by an officer, director or a selected service provider for any reason other than cause, such person shall have a one year period from the date of termination to exercise any option that was vested at the time of the termination of services.

The following table presents the Company’s stock option activity for employees and directors of the Company for the period ended June 30, 2025:

	Number of Options		Weighted Average Exercise Price ($)
Outstanding at December 31, 2024		121,351,132		0.026
Granted		-		-
Exercised		-		-
Forfeited or expired		-		-
Outstanding at June 30, 2025		121,351,132		0.026
Number of options exercisable at June 30, 2025		112,918,837		0.026

The stock options outstanding as of June 30, 2025, have been separated into exercise prices, as follows:

Exercise price		Stock options outstanding		Weighted average remaining contractual life – years		Stock options vested
$		As of June 30, 2025
	0.0011		46,762		1.50		46,762
	0.02		41,237,350		0.11		37,899,088
	0.022		47,128,400		0.11		43,201,033
	0.05		32,938,620		1.55		31,771,954
			121,351,132				112,918,837

Compensation expense recorded by the Company in respect of its stock-based compensation awards for the six months ended June 30, 2025 were $47 thousands and $173 thousands, respectively, and are included in General and Administrative expenses in the Statements of Operations.

As of June 30, 2025, there was $4 thousands of total unrecognized compensation cost related to non-vested options. The cost is expected to be recognized over a weighted average period of 0.25 years.

The aggregate intrinsic value of the awards outstanding as of June 30, 2025 is $0. These amounts represent the total intrinsic value, based on the Company’s stock price of $0.0115 as of June 30, 2025, less the weighted exercise price.

CITRINE GLOBAL, CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

CITRINE GLOBAL, CORP. 10-Q